Won, Annie,Gin, David,Ragupathi, Govind,Livingston, Philip,Adams, Michelle,Perl, Nicholas,Deng, Kai
申请号：
AU2018201645
公开号：
AU2018201645A1
申请日:
2018.03.07
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2018201645A120180329.pdf#####ABSTRACT [003611 The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immune-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favoured adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
